Global Cardiac Arrhythmias Therapeutics Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Cardiac Arrhythmias Therapeutics Market was valued at $42.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 5.8% CAGR, to an estimated market size of $56.3 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global cardiac arrhythmias therapeutics market encompasses pharmacological treatments (including antiarrhythmic drugs and anticoagulants) and interventional medical devices (such as pacemakers, implantable cardioverter defibrillators, and ablation systems) used to diagnose and manage heart rhythm disorders. It excludes general cardiovascular surgical tools not specific to electrophysiology or rhythm management.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Cardiac Arrhythmias Therapeutics Market in the period 2025-30:
- Significant focus on device miniaturization, particularly the adoption of leadless pacemakers and subcutaneous ICDs to reduce procedural complications.
- Integration of AI and machine learning into diagnostic platforms to enable real-time arrhythmia detection and predictive modeling for patient outcomes.
- Rapid clinical shift toward Pulsed Field Ablation (PFA) as a safer, non-thermal alternative to traditional radiofrequency or cryoablation methods.
- Expansion of remote patient monitoring ecosystems that allow for continuous cardiac supervision outside of traditional hospital settings.
- Rising global prevalence of atrial fibrillation driven by an aging population and increasing rates of obesity and hypertension.
- Development of precision medicine and gene therapies aimed at targeting specific ion channel mutations for personalized arrhythmia management.
- Increased adoption of Direct Oral Anticoagulants (DOACs) over traditional therapies due to superior safety profiles and patient adherence.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Implantable CRM Devices
- Antiarrhythmic & Anticoagulant Drugs
- Ablation & Diagnostic Monitoring